美罗华
CD20
医学
单克隆抗体
淋巴瘤
白血病
免疫学
肿瘤科
单克隆
抗原
单克隆抗体治疗
抗体
化疗
癌症研究
内科学
作者
Deborah A. Thomas,Susan O’Brien,Hagop M. Kantarjian
标识
DOI:10.1016/j.hoc.2009.07.005
摘要
Significant advances have been achieved in the treatment of acute lymphoblastic leukemia (ALL) with the incorporation of targeted therapy agents. Targeting leukemia surface antigens with monoclonal antibodies is another promising strategy. This article comprehensively reviews available data regarding the use of rituximab for the treatment of Burkitt-type leukemia/lymphoma and CD20-positive precursor B-cell ALL. The incorporation of rituximab into frontline chemotherapy regimens for Burkitt-type leukemia/lymphoma appears to improve outcome. Preliminary data regarding the use of rituximab in frontline therapy for CD20- positive precursor B-cell ALL suggest its use may also be beneficial, particularly for the younger subsets.
科研通智能强力驱动
Strongly Powered by AbleSci AI